Improved delivery device for cold injection
By using a piston rod and a detector in the drug delivery device, combined with the coordination of the control unit and the motor, the delivery difficulties and patient discomfort caused by the high viscosity of the drug under cold injection conditions are solved, and safe and reliable drug delivery is achieved.
Patent Information
- Application Number
- CN202380028237.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-21
- Filing Date
- 2023-03-21
- Publication Date
- 2024-11-01
AI Technical Summary
Existing drug delivery devices are difficult to deliver drugs effectively under cold injection conditions, especially due to delivery difficulties and patient discomfort caused by high viscosity of the drug, and existing devices lack prevention for side effects caused by cold injection temperature and temporary suspension of delivery. measure.
A conveying device including a piston rod and a detector is designed to prevent blockage of the conveying mechanism by controlling the forward speed of the piston rod at a target speed and reducing the delivery speed when the high viscosity of the drug is detected, and through the control unit and The cooperation of the motor enables safe delivery of drugs.
It effectively solves the problem of delivery difficulties under high viscosity of drugs, reduces patient discomfort, and improves the reliability and safety of the device by reducing delivery speed and pause function.
Smart Images

Figure CN118891071A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a delivery device for a drug delivery device that can be operated at a lower temperature for cold injection. Background Art
[0002] An injection or infusion device is used for subcutaneous delivery of liquid drugs to patients. An injection or infusion device is disposable and used once, or the device is reusable and can be used multiple times. In the latter case, once the previous reservoir is emptied, the reservoir containing the drug can be replaced with a full reservoir. For disposable devices, the reservoir may be present in the device (pre-filled and ready to use), or the user inserts the reservoir into a single-use device. An injection or infusion device has a conveying device for conveying liquid drugs from the reservoir to the patient. The conveying device includes a conveying mechanism powered by an input power pack, and for a manually driven injection pen, the input power can be provided by a patient or a healthcare professional. Alternatively, the power pack can be powered by electricity, pneumatic, hydraulic or spring. The spring drive device may have a pre-tensioned spring, or the user must tension the spring before use. The conveying mechanism is designed to transfer a certain amount of power from the input power pack to the reservoir via the conveying mechanism for drug delivery. The force required to expel the drug from the reservoir depends on, for example, but not limited to, the size of the reservoir, the length of the fluid path, the size of the needle (needle gauge), the size of the plunger advancing within the reservoir, the lubrication of the plunger in the reservoir, the delivery rate, and the viscosity, rheological properties and temperature of the drug. A theoretical model that describes the relationship between viscosity, needle gauge and length, and the pressure difference across the needle is the Hagen-Poiseuille rule, which will be described below.
[0003] The delivery device is designed to deliver a certain amount of output power from the input power pack to the reservoir, and can be optimized in terms of transmission ratio and friction losses, and operate within the working range. Therefore, the working range is constrained by the upper force / speed level that can be achieved. If the viscosity of the drug is too high, the force required for drug delivery may be outside the working range, and the drug may not be delivered at the expected delivery rate.
[0004] The medicine is contained in a reservoir (preferably a barrel or a prefilled syringe). The barrel comprises a barrel made of glass or polymer, which is closed by a pierceable septum on one end and by a movable plunger on the other end. The inner surface of the barrel, septum and plunger forms a volume for the medicine, and the septum can be pierced by a hollow needle for establishing a connection with a fluid path. The movement of the plunger (for example, by a plunger rod that is part of a delivery mechanism) discharges the medicine from the barrel through the fluid path. The prefilled syringe comprises a barrel made of glass or polymer, which can be connected to a needle on one end and comprises a movable plunger on the other end. The needle can be a pile support needle, or is connected to a syringe via a Luer lock connection. The movement of the plunger (for example, by a plunger rod) discharges the medicine from the syringe.
[0005] The medicine in liquid form is based on a preparation comprising an active ingredient and a stabilizer for long-term stability. Long-term stability also includes the long-term stability of physical properties such as the viscosity of the preparation. Most medicines are transported using a cold chain and are subsequently stored in a refrigerator to ensure long-term stability before use, for a long shelf life of the medicine. This also means that due to lower temperatures, the viscosity of the medicine can be higher during storage. When the delivery device is designed for delivery at room temperature, the medicine, the reservoir containing the medicine, and the delivery device containing the reservoir therefore need to be balanced to room temperature before use. The time required for the device to return to temperature depends on, for example, the storage temperature, the ambient temperature, the volume of the medicine, the material used for the reservoir, and the scope of the reservoir encapsulated in the device. Therefore, the return to temperature time can vary between 0.1 and 2 hours, preferably less than 1 hour.
[0006] If the device is taken out of refrigeration and not warmed to room temperature, this will have an effect on the viscosity of the drug, which will be higher, and then the force required to expel the drug from the reservoir may be outside the working range of the device to deliver at the desired delivery rate. This may result in the drug being non-deliverable from the device.
[0007] Additionally, delivery of cold medication to a patient can cause discomfort due to the combination of lower temperature and higher viscosity.
[0008] Furthermore, certain drugs can cause patient discomfort, such as headaches, when delivered at high delivery rates.
[0009] In EP3539592A1, a wearable push injector (WBI) is disclosed that can be attached to the patient's skin for drug delivery. The drug is contained in a barrel and delivered by advancing the plunger in the barrel using a segmented and curved piston rod that is part of the delivery mechanism. The delivery mechanism includes a motor that drives the segmented piston rod using a gear mechanism. The gear ratio of the gear mechanism between the motor and the piston rod can be adapted to accommodate different viscosities of the drug in the barrel unit and / or different needle specifications for skin needles. Therefore, the gear mechanism is designed for the expected viscosity of the drug and cannot adapt to the higher viscosity caused by cold injection, as this will require the gear to be replaced before delivery. In addition, the wearable push injector does not have a preventive measure for temporarily suspending delivery due to patient discomfort caused by low injection temperature or due to side effects associated with the active ingredient.
[0010] EP3875127A1 discloses a drug delivery device comprising a conveying device having a motor and a piston rod that can advance from an initial position to a final position along a thrust axis. A detector detects the rotation speed of the motor using a back electromotive force signal and detects when the piston rod reaches the end of the reservoir.
[0011] WO2011044706A1 discloses a method for controlling a medical drug delivery device with a motor control management, which intermittently actuates a motor for corresponding discharge events for releasing a predetermined amount of drug.
[0012] The object of the present invention is to provide an improved delivery device for a drug delivery device which overcomes the above mentioned disadvantages with respect to cold injection and / or discomfort during delivery. This object is solved by the independent claim and specific variants are disclosed in the dependent claims.
[0013] definition
[0014] The term "drug" or "medicament" includes any flowable medical preparation suitable for controlled administration through a device (such as, for example, a cannula or a hollow needle), and includes liquids, solutions, gels or fine suspensions containing one or more medically active ingredients. The drug may be a composition comprising a single active ingredient, or a premixed or co-formulated composition with more than one active ingredient present in a single container. Drugs include drugs such as peptides (e.g., insulin, insulin-containing drugs, GLP-1-containing drugs or derivatives or similar preparations), proteins and hormones, active ingredients derived from or harvested from biological sources, hormone- or gene-based active ingredients, nutritional preparations, enzymes and other substances in both solid (suspended) or liquid form, as well as polysaccharides, vaccines, DNA, RNA, oligonucleotides, antibodies or parts of antibodies, and appropriate basic, auxiliary and carrier materials.
[0015] The distal end or distal direction is defined by the direction of the needle configured to pierce the patient's skin. For an injection pen, the distal end or distal direction may be the injection needle, and the end of the pen that holds the needle or is configured to hold the needle is the distal end. For an infusion device, the distal end and the distal direction are toward the needle configured to penetrate the patient's skin, which may be along the axis of the device, or oblique or perpendicular to the axis of the device. The distal direction in an infusion device represents the direction of the drug flowing toward the insertion needle. The proximal direction or end is opposite to the distal direction or end.
[0016] In the claims, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality. For example, "a detector" does not exclude the fact that there may be two detectors that functionally or structurally fulfill the purpose of "a detector". The mere fact that certain elements or steps are recited in different claims should not exclude the existence of further meaningful combinations of these elements or steps. Summary of the invention
[0017] The present invention relates to a delivery device for a drug delivery device, comprising a piston rod that can be advanced along a thrust axis from an initial position to a final position, thereby defining a thrust range for the piston rod. The delivery device further comprises: a detector configured to detect when the piston rod reaches the final position, and a delivery mechanism configured to advance the piston rod along the thrust axis. The control unit is configured to control the advancement speed of the piston rod at a target speed, and the thrust range can be divided into at least two zones:
[0018] a final zone, whereby the control unit reduces the target speed to zero once the detector detects that the piston rod has reached the final position, and
[0019] A launch region, whereby if the detector is actuated in this initial launch region of the thrust range, the target speed is reduced to a reduced speed.
[0020] The piston rod for the conveying device may be a rod with or without a thread, and the piston rod may be a hollow or solid (closed) piston rod. The piston rod may be rigid, wherein it does not bend during the intended use, or it is a piston rod intended to be bent along a curve (e.g., along a U-shape). The piston rod may be a multi-segment piston rod, whereby the segments are connected to each other via, for example, a living hinge, so that the piston rod can be bent while still being able to transmit an axial load. The piston rod may also be in the form of a spiral spring or a sphere connected to each other. The U-shaped piston rod may require sufficient guiding devices to guide the piston rod from a straight shape to a curved shape and back to a straight shape. The guiding device may be provided by the housing or housing portion of the conveying device. The piston rod is preferably intended to transfer an axial load to a plunger present in a reservoir while moving along the thrust axis. The advancement of the piston rod along the thrust axis may be a pure straight advancement or a U-shaped advancement.
[0021] Once the drug is discharged, the piston rod may push the plunger in the reservoir from an initial position for a full reservoir to a final position for an empty reservoir. When the reservoir is emptied, the plunger in the reservoir may be prevented from further movement. Thus, the thrust range for the piston rod may be defined by the plunger positions in a full reservoir and an empty reservoir, respectively.
[0022] The delivery mechanism may be a purely mechanical delivery mechanism that uses a power pack to advance the piston rod. Such a power pack may be based on a mechanical spring, a hydraulic or pneumatic source, or a gas generator. The mechanical spring may be based on a torsion spring or a compression spring, using a single spring or multiple springs arranged in parallel or in series. Preferably, an electric power pack is used to drive the delivery device. The delivery mechanism may have a gear mechanism to accelerate or decelerate the rotation initiated by the power pack. As an example, the delivery mechanism may be based on a nut-bolt arrangement between nuts, which has an internal thread that engages the external thread of the piston rod. The rotation of the nut relative to the non-rotating piston rod will advance the piston rod from the initial position to the final position along the delivery direction. This is an arrangement for a solid non-rotating piston rod. Alternatively, the piston rod is rotated by the delivery mechanism and is threadedly engaged with the housing or housing portion of the drug delivery device or the housing portion of the delivery device. The rotation of the piston rod will advance the piston rod along the thrust axis. As a preferred alternative, the piston rod is at least partially hollow, with an internal thread that engages the external thread of the driver (threaded rod) that is part of the delivery mechanism. Rotation of the driver through the delivery mechanism will advance the at least partially hollow piston rod without rotating it.
[0023] For push syringe, the advancement of piston rod can be in single step (once fully advanced along thrust range), or there may be a segmented advancement with multiple advancement steps. Between each advancement step, there may be a time interval, wherein the forward speed for piston rod is set to zero by control unit. For each advancement step, control unit may select different forward speeds for piston rod, for example, forward speed is set to predetermined target forward speed or reduced speed. Target speed may be selected from a group of predetermined target speeds, and / or reduced speed may be selected from a group of predetermined reduced speeds. Selection may be based on the selection of input parameters or specific drugs from health care professionals to complete, or may be based on the data received from sensors (such as, for example, temperature sensors or flow sensors) to complete. Selection may be received by control unit from input data from sensors or from remote devices (such as control devices that may be wirelessly connected to drug delivery devices) to complete. Selection may also be based on internal timer to complete, the internal timer may be for example, by drug delivery devices from the removal of its packaging, or by release liner from patch devices, or by pressing or actuating devices or wirelessly connected to the start button on the remote device of drug delivery devices to start.
[0024] The control unit may be a purely mechanical controller based on a brake, delay or connecting rod movement mechanism. More preferably, the control unit is an electronic control unit, which may be part of and located on a printed circuit board (PCB) and controls the electrical components for controlling the forward speed of the piston rod. The control unit preferably comprises a memory or storage unit for storing predetermined data, such as a target speed, a reduced speed or a waiting time or a cumulative maximum time value or a time limit. Furthermore, the control unit may comprise an integrated circuit.
[0025] The detector is used for multiple purposes; the detector is configured to detect the final position once the piston rod advances into the final zone of the thrust range and reaches the final position of the piston rod. Preferably, the final position corresponds to a position at which the piston rod is prevented from moving further, and therefore, the conveying mechanism cannot advance the piston rod. Once the piston rod pauses, it is important to close the conveying mechanism to prevent damage to the conveying mechanism for the drug delivery device. The final position may depend on the dimensional tolerance of the reservoir (e.g., the neck of the glass barrel), and therefore may vary between devices. Once the detector detects the final position in the final zone of the thrust range, the control unit reduces the target speed to zero, for example, the conveying mechanism is preferably permanently switched to a closed state. Preferably, for a disposable drug delivery device, the control unit is programmed to make the conveying mechanism irreversible: the forward speed of the piston rod can be increased to a level different from zero. For a reusable drug delivery device, the piston rod for the conveying mechanism can be reset to an initial position from the final position, and a new drug reservoir can be inserted. The control unit can be reset to make the conveying mechanism configured to advance the piston rod again at the target speed for the new reservoir after replacing the empty reservoir.
[0026] If the piston rod is in the initial part of the initiation zone or thrust range, the same detector used to detect the final position in the final zone is used to detect the pause of the piston rod. If the detector is actuated in the initiation zone and detects that the piston rod does not move, the detector sends a signal to the control unit, and the target speed is reduced to a reduced target speed. The conveying mechanism initially sets the forward speed for the piston rod to the target speed, which is predefined by the target rotation speed of the rotor for the motor. The target rotation speed is preferably stored in the storage unit. The conveying mechanism is designed for the operating range of the forward force and forward speed that can be achieved by the conveying mechanism, and if the conveying mechanism cannot rotate the motor at the target rotation speed (for example, due to the higher viscosity of the drug), the detector detects the non-rotation in the initiation zone. The higher viscosity can be due to the lower temperature of the drug stored at a lower temperature in a refrigerator, and the drug is inserted into the delivery device without allowing the drug to return to room temperature. Alternatively, the prefilled drug delivery device including the drug reservoir is taken out of the refrigerator and used without allowing the prefilled device to return to room temperature. The viscosity of the cold drug will be higher, thus resulting in a higher force required to discharge the drug from the delivery device. The force required to advance the piston rod at a reduced target speed and discharge the cold drug with a higher viscosity is reduced (Hagen-Poiseuille's law), so that the cold drug will be discharged at a reduced delivery rate. Optionally, the controller is programmed to further reduce the forward speed of the piston rod to a second reduced target speed if the detector is still actuated and detects that it is not advancing at a reduced target speed in the initiation zone. This process can be repeated until the target speed that is finally reduced does not successfully advance the piston rod at the target speed that is finally reduced, and the control unit can send an alarm signal to the user. The advantage of reducing the target speed to a reduced target speed or further reducing the target speed to a second, third, etc. reduced target speed is that even if the instruction to rewarm the device is ignored, or if the device is taken away from the refrigerator in an emergency, the drug can be discharged from the drug delivery device.
[0027] There may be a transition time between switching from the target forward speed to the reduced speed. The transition time or holding time means that the forward speed is temporarily automatically set to zero by the control unit, and after a predetermined transition or holding time, the control unit automatically sets the forward speed from zero to the reduced target speed. The holding or transition time before switching to the second or third reduced target speed may be longer than the holding / transition time before the first reduced target speed. The conveying mechanism may include a gear mechanism that is tightened when the conveying mechanism initially attempts but fails to advance the piston rod at the target speed. The transition time before switching to the reduced target speed is intended to reduce the stress accumulated in the conveying mechanism. This prevents damage to the conveying device and then improves reliability. In addition, the holding / waiting time means that the temperature of the drug rises, so that the viscosity decreases, and the device can be operated at the reduced target speed. This also improves the reliability of the device when it is taken directly from the refrigerator without getting hot.
[0028] In an example, the initiation zone of the delivery device is defined by the initial portion of the thrust range, and the final zone is defined by the final portion of the thrust range. The initiation zone is defined by less than 30% of the initial portion of the thrust range reached by the piston rod, and the final zone begins at more than 80% of the final portion of the thrust range.
[0029] The thrust range may be subdivided into at least an initiation zone for an initial portion of the thrust range and a final zone for a final portion of the thrust range. The initiation zone is defined by less than 30% of the initial portion of the thrust range, preferably less than 20% of the initial portion of the thrust range, more preferably less than 10% of the thrust range, and most preferably less than 5% of the thrust range. The final zone begins at more than 80% of the final portion of the thrust range, more preferably more than 90% of the thrust range, and most preferably more than 95% of the thrust range. Between the initiation zone and the final zone, there may be other zones within the thrust range, such as a blocking zone, in which, when the detector is actuated, an alarm signal is generated and directed to an acoustic or optical signaling unit. The alarm signal may indicate that the drug is not deliverable due to a blockage in the flow path of the drug. The advantage of dividing the thrust range into several zones is that in each zone a specific response can be initiated by the control unit still using a signal from the same detector.
[0030] In another example, the target speed of the delivery device is gradually or continuously reduced to zero or to a reduced speed. The continuous reduction may be advantageous in gradually reducing the mechanical stress accumulated in the delivery mechanism trying to advance the piston rod at the target speed.
[0031] The reduced speed for the delivery device may be less than 60% of the target speed. The reduced speed may be less than 60% of the target speed, preferably less than 50% of the target speed, most preferably less than 40% of the target speed. The second reduced speed may be less than 50% of the target speed, preferably less than 40% of the target speed, most preferably less than 30% of the target speed. The third reduced speed may be less than 40% of the target speed, preferably less than 30% of the target speed, most preferably less than 20% of the target speed. The reduction in the target speed will increase the injection time to deliver the amount of drug present in the drug delivery device.
[0032] In yet another example, the target speed in the initiation zone is first reduced to zero before being set to a reduced speed. The reduction in speed to zero initiates the above-mentioned transition time or holding time in the conveying mechanism for stress relaxation.
[0033] In another example, the piston rod of the delivery device can be advanced using an electric drive including an electric motor, and the detector can be activated by detecting non-rotation or limited rotation of the electric motor. The delivery mechanism of the delivery device can use an electric motor to advance the piston rod. The electric motor is powered by a battery or accumulator, and the rotation of the rotor of the electric motor is used to advance the piston rod. If the piston rod cannot be advanced, for example in the final zone (where the reservoir is emptied and the piston rod reaches its final position), or in the initiation zone (where the barrel is full but cannot be advanced due to the increased viscosity of the drug), the non-advancement of the piston rod will result in non-rotation or limited rotation of the electric motor due to its mechanical engagement with the delivery mechanism, thereby activating the detector. Limited rotation is defined as less than 70% of the expected rotation speed (revolutions / second) that can be achieved, preferably less than 50% of the expected rotation speed that can be achieved, and most preferably less than 30% of the expected rotation speed.
[0034] The detector preferably detects or is based on detecting the rotation or non-rotation of the motor by measuring the number of steps of the motor, or measuring the back electromotive force signal, or using an encoder, or measuring the motor current. Measuring the number of steps and step loss of the motor indicates that the motor cannot be driven as expected, and then initiates a detection signal to the control unit. The control unit can use a comparator to compare the number of steps or the accumulated number of steps with the stored value, and if there is a deviation, non-rotation is detected. Alternatively, the back electromotive force signal generated by the motor is used to detect the rotation or non-rotation of the motor. In another alternative, an encoder (such as a magnetic or optical encoder) is used to detect the rotation or non-rotation of the motor.
[0035] In yet another example, the control unit actuates the motor of the delivery device for advancing the piston rod at a target speed by rotating the motor at a target rotational speed, and when the final position for the piston rod is reached and detected by the detector, the control unit reduces the target rotational speed of the motor to zero, or when the detector is actuated in the ignition zone, the control unit reduces the target rotational speed to a reduced rotational speed for advancing the plunger at a reduced speed. The target rotational speed for the motor is transmitted to the piston rod using a delivery mechanism that may include a gear mechanism, and thereby, the target rotational speed is converted into a linear advancement speed for the piston rod.
[0036] In another example, the control unit of the conveying device may receive information from the detector and measure and meter the number of revolutions or steps of the motor and compare the accumulated number of revolutions or steps with the stored value. If the accumulated value is lower than the stored trigger value when no rotation is detected, the target rotation speed is reduced to the reduced rotation speed, and if the accumulated value is higher than the stored upper limit value, the target rotation speed is reduced to zero. Therefore, the trigger zone is defined by the range between zero turns and the trigger value, and the final zone starts from the upper limit value for the accumulated number of turns. The stored value is stored in the storage unit, and if the accumulated value representing the number of revolutions of the motor is lower than the trigger value, the piston rod is still in the trigger zone of the thrust range. As long as the piston rod is in the trigger zone and the accumulated number of revolutions is lower than the trigger value, the target rotation speed for the motor is reduced to the reduced rotation speed. Optionally, there is a transition time or a holding time between detecting no rotation in the trigger zone and setting the rotation speed to the reduced rotation speed.
[0037] As another example, the control unit may actuate a first optical and / or acoustic signal when the piston rod advances at a target speed, and may actuate a second optical and / or acoustic signal different from the first signal when the piston rod advances at a reduced target speed, and may actuate a third optical and / or acoustic signal different from the first signal and the second signal when the piston rod reaches the final position. The optical signal may be based on a purely mechanical indicator, or the mechanical member may be rotated by a motor. For example, the optical indicator may be mechanically moved into a window in the housing of the drug delivery device and may be visible in the window. Alternatively and preferably, the optical indicator is electrical and based on a light source, such as an LED indicator visible in an observation window or through a translucent portion of the housing. There may be multiple optical indicators, such as multiple LED lights, all of which have the same color or different colors. Multiple LED lights may form a pattern, and may indicate, for example, by flashing a frequency, that the device is operated for the expected target speed of the piston rod. In addition, the LED indicator may be oriented in an array and may be actuated in sequence depending on the amount of drug delivered from the device, thereby forming a status indicator. The acoustic signal may be based on a buzzer or speaker that is part of the control unit. Optionally, the first optical signal signals at a first color, and the second and third optical signals signal at different colors. Optionally, the first acoustic signal may be at a different frequency than the second or third acoustic signal.
[0038] In another example, when the accumulated number of revolutions is between the initiation value and the upper limit value, the target rotational speed for the delivery device may be reduced to zero, and the control unit actuates a fourth acoustic and / or optical alarm signal, indicating that a blockage has occurred in a blockage zone located between the initiation zone and the final zone. Actuation of the detector in a zone of the thrust range between the initiation zone and the final zone may indicate a malfunction during delivery, such as a blockage in the fluid flow path of the drug, thereby increasing safe operation of the device for the user.
[0039] Alternatively, the delivery device may include a pause button, which, when pressed, temporarily pauses drug delivery by temporarily setting the target rotation speed of the motor to zero. All of the above-mentioned examples for the delivery device (including being used to reduce the forward speed for the piston rod to a reduced speed in the initiation zone, or reducing the forward speed to zero in the final zone, or introducing the feature of transition / holding time during the initiation zone) are all controlled by the control unit, and are included in the automatic or programming steps performed by the device when the user or healthcare professional actuates the drug delivery device. The pause button is intended to temporarily pause drug delivery and the device is set in a pause mode. After starting to deliver, for example, after actuating the device by, for example, pressing a start or actuation button, the pause button is pressed or actuated by the user or healthcare professional. Alternatively, a capacitive sensor is used as a start button to start actuation. Therefore, the pause button can veto the step initiated by the control unit after starting injection. After pressing the pause button for the second time, the control unit can continue drug delivery. The time interval for the pause mode between the first actuation and the second actuation of the pause button defines the pause time. There may be a maximum pause time stored in a storage unit of the control unit, and once the pause time exceeds the maximum pause time, the delivery device automatically returns to advance the piston rod, or alternatively, the injection is terminated. The pause button can be pressed more than once, thereby setting the device in the pause mode again. There may be no limit setting for the number of times the pause button can be pressed to actuate the pause mode. Alternatively, the number of times for actuating the pause mode can be limited to four times, preferably three times, most preferably two times. The maximum pause time for cumulative pause is constrained to one hour, preferably thirty minutes, more preferably twenty minutes. The pause button can be a button that can be pressed on the drug delivery device, or the pause mode is initiated via a remote device wirelessly connected to the drug delivery device. The drug delivery device may have a timer included in the control unit, which measures the time required for delivery at a target speed, at a reduced speed, measures the holding time, and the time the metering device operates in the pause mode. The cumulative time value can be compared with the maximum time value for drug delivery, and once the maximum time value is reached, a timeout signal or an alarm signal can be initiated. The maximum time value may be four hours, preferably three hours, more preferably two hours, most preferably one hour.
[0040] Optionally, the pause mode is accompanied by a fifth acoustic and / or optical signal. The fifth acoustic signal may be a melody indicating the start of the pause mode, and the same melody is played to indicate the end of the pause mode for resuming drug delivery. The melodies at the start and end of the pause mode may be opposite. Alternatively, the acoustic buzzer signal is actuated at the start of the pause mode, which is different from the signal at the end. The difference may be a different buzzer frequency or a different noise level. The pause mode may be accompanied by a specific pause melody, which is different from the melody for delivery at the target speed or different from the melody for delivery at a reduced target speed. The pause function may be enabled or disabled for the drug delivery device. The pause function may be enabled by default on the device and disabled by pressing the pause button for a longer period of time (e.g., at least three seconds, preferably at least five seconds, more preferably at least ten seconds). The pause function may also be enabled or disabled using a remote device including a control application for the drug delivery device.
[0041] The pause button for activating the pause mode may be the same button as the actuation button for starting drug delivery. After drug delivery is started by pressing the actuation button once, the button may automatically and irreversibly switch from the actuation button function to the pause button function. Alternatively, the actuation button may be pressed for a longer period of time and thereby switch from the actuation button function to the pause button function. The pause button may automatically return to the function of the actuation button, or it may require another extended press of the pause button for returning to the actuation button function. Drug delivery (cold injection) of drugs with high viscosity and / or lower temperature may cause patient discomfort, and therefore the patient may use the pause button to delay drug delivery. In addition, some drugs may cause local pain or headaches when delivered once, requiring a pause button.
[0042] The drug delivery device including the conveying device described above further includes a reservoir for accommodating medicine and a plunger for discharging medicine from the delivery device through the outlet of the reservoir by moving the drug in the reservoir by a piston rod. The drug delivery device can be an injection or infusion device, which can be a reusable device or a disposable device. The drug delivery device can be a patch device, such as a patch pump or a wearable push syringe (WBI). The reservoir is preferably a rigid reservoir made of glass or plastic material (such as cycloolefin polymer (COC) or polypropylene (PP)). The reservoir can be a prefilled syringe, which includes a needle or an outlet with a Luer lock at the distal end, or the reservoir is a barrel closed by a pierceable diaphragm at the distal end. The barrel preferably includes a cylindrical wall section, which has an opening closed by a diaphragm and an opening opposite to the first opening closed by a movable plunger. The volume between the wall, the plunger and the diaphragm can be used for medicine. The plunger rod advances the plunger toward the outlet with the linear advancement of the target forward speed (for example, in mm / min), thus reducing the volume available for medicine, thus discharging medicine according to the target delivery rate (for example, in ml / min).Except the patch device above, the drug delivery device can also be a pen-shaped injection device, which is hand-held by the user during injection and does not have a patch or adhesive layer.The reservoir can be a prefilled syringe, which includes a pin and a plunger, and the plunger advances along the distribution direction by a non-manual driver (such as a motor powered by a battery).Specifically, the injection device can be an electronically controlled automatic injector, which is suitable for distributing the entire volume of the reservoir in a single injection event in a time period exceeding 30 seconds, preferably exceeding 5 minutes.
[0043] Drug delivery device, the initial position of piston rod is defined by the plunger position for the reservoir filled, and the final position is defined by the plunger that prevents the plunger from advancing further (preventing the piston rod from advancing further) by engaging the neck region of the reservoir. The reservoir is preferably a barrel with a wall, and the wall forms a barrel for moving a cylindrical plunger, which has a first diameter adjusted to the inner diameter of the barrel. The barrel can be made of glass or polymer. The diameter of the barrel is reduced near the diaphragm, forming a neck region to adapt to the outer dimensions of the diaphragm. When the plunger with the first diameter is not adaptable or passes through the neck region with a smaller diameter, the plunger can move from the initial position near the proximal end until the neck region. As an example, the drug delivery device is a wearable push syringe. The push syringe is preferably pre-filled and ready to use, and includes an adhesive for adhering the device to the patient's skin.
[0044] The drug delivery device may further include a reservoir having a plunger, the plunger being able to move from an initial position to a final position within the reservoir at a target speed, defining a thrust range, thereby expelling the drug from the delivery device. The drug delivery device further includes: a detector configured to detect when the plunger reaches the final position in the reservoir, and a conveying mechanism configured to convey the plunger in the reservoir at the target speed. The control unit of the drug delivery device is configured to control the target speed, and when the detector is actuated and detects when the plunger reaches the final position, the target speed is reduced to zero. The drug delivery device is characterized in that if the detector is actuated during the initiation zone of the device, the target speed is reduced to a reduced speed.
[0045] In another example, the drug delivery device includes a reservoir and a movable plunger for accommodating the drug. The delivery mechanism is configured to preferably use a piston rod to advance the plunger toward the outlet of the reservoir to discharge the drug from the device. The control unit includes a control circuit for controlling the delivery mechanism, and a start button, which, when pressed, starts a delivery mode for drug delivery by actuating the delivery mechanism. The drug delivery device further includes a pause button, which is preferably a part of the control circuit, and when pressed, the pause button pauses drug delivery by temporarily deactivating or stopping the delivery mechanism, thereby starting the pause mode. Once the pause button is pressed for the second time, the delivery of the drug is resumed, thereby defining the pause time, wherein when the pause time exceeds the maximum pause time value stored in the storage unit, the delivery mode is automatically resumed. Alternatively, once the pause time exceeds the maximum value stored, the injection is completely terminated. Optionally, the length of the maximum pause time in the pause mode can be configured or selected from the range of the maximum pause time, and the pause mode can be actuated multiple times. The pause time can be recorded and accumulated by the control unit and compared with the maximum accumulated pause time in the storage unit, and once the accumulated pause time exceeds the maximum accumulated pause time, the delivery mode is automatically activated. Optionally, the number of times the pause mode can be activated can be configured by the user, and the pause mode can also be enabled or disabled by the user.
[0046] An acoustic and / or optical pause signal different from the acoustic and / or optical delivery signal during the delivery mode can be generated by the control unit during the pause mode, and when switching from the pause mode to the delivery mode, or vice versa from the delivery mode to the pause mode, an acoustic and / or optical resume signal different from the pause signal or the delivery signal is generated. For example, the acoustic signal includes a tone sequence, and the tone sequences for the pause signal and the delivery signal are opposite. Optionally, the pause button is equal to the start button, the start button can be switched to the pause button by long pushing the start button, or the start button is a two-step push button. The advantage of the pause button is that the pause mode can be delivered once the patient perceives discomfort during drug delivery. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Although the invention is described in detail in the following drawings and the foregoing summary of the invention, such description is to be considered illustrative or exemplary and not restrictive. Variations on the disclosed embodiments may be understood and implemented by those skilled in the art from a study of the drawings, the disclosure, and the appended claims and practice the claimed invention.
[0048] Figure 1 : Wearable push injector.
[0049] Figure 2 : Figure 2 Cross-section of a wearable bolus injector.
[0050] Figure 3 : Details for the delivery device and needle insertion device.
[0051] Figure 4 : Schematic representation of the temperature and viscosity of a drug after rewarming from refrigeration.
[0052] Figure 5 : Schematic diagram of delivery at target speed and detecting when the piston rod reaches the final position in the final zone.
[0053] Figure 6 : Schematic representation of the target velocity and reduced velocity in the initiation zone during cold injection.
[0054] Figure 6 : Schematic diagram for cold injection including transition time
[0055] Figure 7 : Schematic diagram for cold injection with transition time and pause button actuated.
[0056] Figure 8 : Schematic diagram for cold injection with transition time and occlusion detection.
[0057] Fig. 9 : Schematic diagram for delivery at target speed including pause mode.
[0058] Fig.10 : Schematic diagram for cold injection with transition time and pause mode. DETAILED DESCRIPTION
[0059] exist Figures 1 to 3, including drug delivery according to the delivery device of the present invention. The drug delivery is a wearable push injector WBI1. Alternative drug delivery devices (such as automatic pens, insulin pumps, patch pumps, patch injectors or electric automatic injectors) can also accommodate the delivery device according to the present invention. WBI1 includes a housing 2 that encapsulates and / or holds the units that constitute the delivery device. The housing 2 may have an observation window 6 for observing at least a portion of the drug reservoir. The observation window 6 may be a portion of a separate cover that is attached or can be attached to the housing 2. The housing may have a status indicator 7. The status indicator may be based on a translucent or transparent portion of the housing, which is backlit by a light source (e.g., multiple LED lights). The status indicator 7 can be used to indicate delivery progress, delivery speed, or whether the device is operating at a target delivery rate / speed or at a reduced delivery rate / speed. The status indicator can also indicate the general status of the device, such as "ready", "delivery completed" or "ready to be removed from the skin". The WBI may have a second LED indicator 10, which can be used to indicate a connection with an external device, such as indicating that a Bluetooth connection is established or lost. Alternatively, the second LED indicator is used to indicate whether connection establishment is possible. Or in other words, the device is visible to other devices for connection. The second LED indicator may have a different color than the status indicator 7. For example, blue may be used to indicate connectivity with an external device. A different color (e.g. red) may be used for the status indicator 7 and / or the second LED indicator 10 to indicate a malfunction of the device, such as "blocked" or "battery exhausted" or "lost connection".
[0060] The start button 3 is accessible to the user for actuation of the WBI. The start button 3 is preferably a push button that can be flush with the housing 2 or can extend from the housing. Alternatively, the button is a pull-up button. The push-down or pull-up button can be multi-stage, such as a two-stage button, whereby one push-down / pull-up level initiates a delivery mode for drug delivery, and the second level can be used to start a different mode, such as, for example, a pause mode, or a final mode for device disposal, or a mode for resetting (reusable) drug delivery devices. Optionally, there may be a second push-down or pull-up button 8 separated from the start button 3. Alternatively, reference numeral 8 identifies another position for a Bluetooth status indicator. Buttons 3 and 8 can also be actuation buttons using a capacitive sensor (touch sensor). The second push-down / pull-up button can also be used to start different modes. The WBI is constructed to be attached to the patient's skin using a patch 5 including a skin adhesive. The patch 5 has at least a second adhesive layer for attachment to the bottom surface of the housing 2. The patch 5 is preferably a multilayer system, which includes a carrier layer and at least two adhesive layers mentioned above. The carrier layer can be a woven layer made of natural cotton fibers or polymer fibers, for example. The skin adhesive can be based on acrylic resins. A combination of common adhesives and pressure-sensitive adhesives can be used. The skin adhesive layer for the patch 5 is covered by a release liner 4 to prevent the unintentional attachment of the delivery device and to protect the skin adhesive before use. The release liner 4 can be based on paper or a polymer film (e.g., a polyester film), and one or both surfaces of the film can be coated with a non-adhesive coating. The release liner 4 can have a pull tab 9, which optionally has an opening to facilitate gripping the release liner.
[0061] Figure 1The drug delivery device presented in the invention comprises at least the following units: a reservoir unit including a reservoir holder for holding a reservoir, a delivery unit for discharging a drug from the reservoir, a patch unit for attaching the device to the skin, a needle insertion unit including a fluid path, and a control unit for controlling the delivery unit and the needle unit. All units are housed in a housing 2, which provides the units with protection from the surrounding environment and mechanical support. The control unit can be configured to communicate with an external device, preferably via a Bluetooth connection. The needle insertion unit comprises at least a hollow skin insertion needle and a skin insertion mechanism. The skin insertion mechanism is configured to move the end of the skin needle from a position within the housing to a position outside the housing. The housing 2 comprises an orifice for the skin needle, which can be covered by a sterile barrier before use. The needle unit further comprises a pipeline connected to the skin needle, which guides the fluid from the reservoir through the skin needle. The other end of the pipeline can be directly connected to the reservoir, or include an additional needle, which can be moved from a position within the needle unit toward the reservoir unit to connect the fluid path of the needle unit to the reservoir in the reservoir unit. The above mentioned fluid path is formed by at least tubing, hollow skin insertion needle and optionally additional hollow needle. The patch unit comprises a multilayer patch with skin adhesive and housing adhesive and may further comprise a skin contact sensor, such as a capacitive sensor. Examples and details for the unit are presented below.
[0062] Figure 2 The control unit 11 shown in is preferably located on a printed circuit board (PCB) that includes an integrated circuit, a storage unit, and an LED light 12 positioned adjacent to a transparent housing section 13. The array of LED lights 12 may be part of and form a status indicator 7. The start button 3 may actuate a switch on the PCB to start or pause drug delivery. In the present example, the button may be pressed down one level to start the device. Alternatively, the push button and PCB switch may allow different functions depending on the pressure applied or the position of the push button relative to the housing, or the amount of time the pressure is applied. The delivery device includes a piston rod 14, a battery 15, an electric motor 17, and a gear mechanism that will be in operation at the same time. Figure 3 1. The battery 15 is enclosed in a battery holder and the electrical contacts may directly contact the PCB. The motor 17 is housed in the delivery unit and may also have electrical contacts 31 that contact the PCB. The PCB may further have a transmitter / receiver for connecting to an external device and / or the PCB may further include a buzzer and / or the PCB may include a speaker for acoustic signaling.
[0063] Details for the delivery device 19, the needle unit 18 and the reservoir unit with the reservoir 32 are given in Figure 3. The reservoir unit comprises a barrel 32, which is closed at one end by a movable plunger 33 and at the opposite end by a septum 35. The septum is preferably connected to the neck 34 of the barrel by crimping. The neck 34 has a reduced diameter compared to the barrel of the barrel that receives the movable plunger. Optionally, the septum is covered by a sterile barrier film that can be removed before drug delivery. The needle unit 18 comprises a skin needle insertion mechanism 26, which is configured to move the skin needle 29 from a retracted position to an extended position. The insertion mechanism is preferably spring-driven. The skin needle insertion mechanism can also be configured to retract the skin needle 29 from an extended position to a retracted position. The needle unit 18 further comprises a barrel needle insertion mechanism 27, which is configured to insert a barrel needle 30 through the septum of the barrel 32. The tube 28 connects the barrel needle 30 with the skin needle 29 to establish a fluid connection between the drug in the reservoir and the patient. The tube and the two hollow needles are part of the fluid path. The needle unit 18 is enclosed in a needle unit housing not shown. The needle unit housing comprises at least two passages for the skin needle 29 and the barrel needle 30, and both passages may be covered by a removable film. A further passage may be available for a cam shaft as discussed below. Preferably, the needle unit 18 is sealed from the surrounding environment and sterilized. The passages may be sealed by a seal, for example by a sealing ring for the cam shaft 25, or the passages may be covered by a removable film, such as a Tyvek film. The skin needle and the barrel needle in the needle unit 18 are preferably oriented perpendicular to each other.
[0064] The delivery device 19 comprises a segmented piston rod 14 having a segment 20, a first segment 22 and a last segment 23. The segments 20 for the segmented piston rod 14 are connected to each other by hinges so that the piston rod can be bent and form a U-shaped piston rod. The piston rod 14 is guided by a housing, not shown, of the delivery device. The last segment 23 is suitable for directly or indirectly abutting a plunger 33 in a barrel, and the advancement of the piston rod 14 will advance the plunger for discharging the drug from the device. A barrel adapter may be provided between the last segment 23 and the plunger 33. The piston rod 14 is advanced by the rotation of a threaded rod 21, which has an external thread that engages the internal thread of the first segment 22 of the piston rod 14. The piston rod 14 is guided by the housing of the delivery unit so that the piston rod cannot rotate around its own axis while being able to form a U-shaped configuration due to the hinge between the segments. The rotation of the threaded rod 21 advances the piston rod 14 and therefore advances the plunger 33 in the barrel. For an at least partially filled cartridge, the plunger can be advanced from the initial position until the plunger reaches the neck 34 of the cartridge, as the neck portion prevents further movement of the plunger 33. The delivery unit 19 further comprises a motor 17 and a battery 15. The rotation of the motor 17 is transmitted to the threaded rod 21 via a gear mechanism 24.
[0065] The motor 17 is preferably configured to operate in two rotational directions, with rotation in a first rotational direction being transmitted to the threaded rod 21 via a gear arrangement, and rotation in the opposite direction being transmitted to the cam shaft 25. The cam shaft 25 is part of the needle unit, and rotation of the cam shaft 25 controls the release of the skin needle insertion and the cartridge needle insertion. The gear arrangement 24 may include a one-way ratchet system so that only one rotational direction is transmitted to the cam shaft 25 or to the threaded rod 21.
[0066] The delivery device includes a detector for detecting when the piston rod 14 reaches the final position in the barrel 32. When the plunger 33 advances to the distal end of the barrel, the distal end of the plunger then contacts the neck 34 of the barrel 32 and prevents the plunger from moving further. The barrel is emptied and no further drug can be discharged. Since the plunger 33 cannot advance further, the piston rod 14 is also prevented from moving further, and this will stop the rotation of the threaded rod 21, the gear device 24, and finally the rotation of the motor 17. Due to the tolerance and elasticity of the transmission system, when the plunger 33 reaches its final position, the rotor of the motor 17 may continue to rotate for a short period of time. This may lead to accumulated mechanical stress in the delivery device. The motor may have a detector for detecting the rotation or non-rotation of the motor. The detector may include an encoder integrated in the motor or a separate component. The encoder may be an electrical encoder, an optical encoder or a magnetic encoder. The optical encoder may be based on a wing wheel positioned between a light source and an optical detector. The wing wheel will typically be connected to the output of the motor to indicate rotation. An example of a magnetic encoder is a Hall sensor. Alternatively, the detector may also detect an electrical signal such as a back electromotive force voltage, or measure the motor current for detecting rotation or non-rotation of the motor. In this example, the detector is based on detecting a back electromotive force signal.
[0067] When the piston rod is at rest, the detector detects rotation or non-rotation of the motor. This may be because the plunger has reached a final position after expelling all the drug that can be delivered from the device, or because there is a blockage in the fluid path (for example in the insertion needle 29 or tube 28), preventing further drug delivery, or because the drug is removed from a cold state without rewarming (so-called cold injection). In the latter case, the viscosity is too high, preventing delivery. In all cases, the detector detects non-rotation and sends a signal to the control unit, which will send different instructions to the motor depending on the position of the piston rod along the thrust range 40:
[0068] In the final region 38 of the thrust range 40, the control unit will stop sending instructions to the motor to continue or attempt rotation of the motor's rotor because the cartridge is empty. The target rotation speed for the rotor will be set to zero. The control unit may actuate an acoustic and / or optical signal for successful completion of drug delivery. Details will be provided in Figure 5 Presented and discussed in.
[0069] In the initial initiation zone 37 of the thrust range 40, the control unit will reduce the rotational speed of the motor to a reduced rotational speed, resulting in a reduced advancement speed for the piston rod. The control unit may actuate different signals for signaling, for example, a cold injection. Details will be described in Figure 6 and Figure 7 Presented and discussed in.
[0070] In the blocking zone 39 between the initiation zone and the final zone, the control unit sets the target rotation speed of the motor to zero and may activate an alarm signal. Details will be given in Figure 8 Presented in.
[0071] In the following, fluid flow through a hollow needle (e.g., barrel needle 30 or skin needle 29) is described according to the Hagen-Poiseuille equation (HPE). The HPE describes the laminar flow of an incompressible fluid with viscosity η through a needle of constant diameter (r) and length (1). The pressure drop (ΔP) required to deliver the rate (dV / dt) is given by:
[0072]
[0073] As the viscosity η increases with decreasing drug temperature, the pressure drop ΔP also needs to increase for a constant delivery rate. The pressure drop ΔP is the pressure difference at the inlet and outlet of the needle. For delivery from a cartridge, this pressure drop is calculated by dividing the force applied to the plunger (by the piston rod) by the surface area of the plunger (N / mm 2 The higher the pressure P on the plunger, the higher the force F required, and there is a maximum force that the delivery mechanism can deliver, which can lead to clogging of the drive train when a target delivery rate is selected at a certain viscosity.
[0074] At a constant pressure P (or force F delivered by the delivery mechanism) and a constant length l, the ratio between the target delivery rate (η1) and the reduced delivery rate (η2) can be calculated as:
[0075] Varget*n1=Vreduced*n2 。
[0076] Schematic diagram of the change of drug viscosity (η) and temperature (T) over time. Figure 4. If the drug is removed from a cold state (e.g. from a refrigerator at 5 degrees Celsius), the viscosity (ηl) is higher than the rewarmed drug (η2) at 20 degrees Celsius. Injection without rewarming (cold injection) will increase the force required for delivery and may exceed the operating range of the delivery mechanism. Reducing the delivery rate by reducing the forward speed of the piston rod from the target speed (Vtarget) to the reduced speed (Vreduced) allows drug delivery without changing the mechanical structure of the delivery device (e.g., gearing mechanism) (as suggested in prior art EP3539592).
[0077] exist Figures 5 to 10 In the present invention, exemplary embodiments of a drug delivery device for or comprising a delivery device are presented, which drug delivery device is suitable for cold injection and / or comprises a pause mode. The delivery device is preferably such as Figures 1 to 3 A delivery device for WBI is depicted in FIG.
[0078] Figure 5 A schematic diagram for successful delivery of a drug at a target speed / delivery rate is presented. The device including the drug and the conveying mechanism is warmed to room temperature, and the viscosity changes accordingly. The user removes the release liner and attaches the drug delivery device to the skin, and starts delivery by pressing the start button 3. The needle unit 18 is actuated, and the needles 29, 30 are inserted into the skin and the barrel to establish a fluid connection between the patient and the drug in the barrel. The control unit actuates the motor 17, and the piston rod 14 can advance at the target speed, whereby the rotor of the motor 17 rotates at the target rotation speed. The back electromotive force signal is detected and the signal is sent to the control unit, and the control unit measures and accumulates the number of revolutions. The accumulated number of revolutions is compared with the stored upper limit value, and with respect to the upper limit value, the final zone 38 for the thrust range 40 is reached. Non-rotation is detected in the final zone 38 (when the back electromotive force signal is no longer available) and the target rotation speed for the motor is set to zero. Delivery from the device is successfully completed, and the control unit can actuate an acoustic or optical signal accordingly. In addition, the needle unit is actuated to retract the skin needle from the patient. Another optical and / or acoustic signal may be provided to indicate to the user that the device may be removed from the skin. Optionally, a wait time or dwell time is initiated between completion of delivery and removal of the device. This allows sufficient time for the tissue to adapt or diffuse the drug within the tissue prior to removal. An acoustic and / or optical signal may be transmitted to the user, signaling delivery at a target delivery rate.
[0079] Figure 6A schematic diagram for cold injection is shown. The device is removed from the refrigerator and used without warming to room temperature, resulting in a higher viscosity for the drug. The control unit 11 initially commands the delivery device to deliver at a target speed. However, the viscosity is too high and prevents delivery at the target speed, and the detector is activated in the initiation zone 37 or initial zone of the thrust range 40. Therefore, when no rotation is detected, the accumulated number of revolutions detected is lower than the initiation value because no back EMF signal is received by the control unit. In this example, the initiation zone 37 is defined as less than 10% of the thrust range 40. The control unit commands the motor to deliver the drug at a reduced speed, and the back EMF signal for rotation is received by the control unit, which measures and accumulates the number of revolutions at the reduced speed. When the plunger reaches the final position in the final zone 38 of the thrust range 40, the detector is activated again, resulting in no rotation of the motor, and the reduced target speed is further reduced to zero. Acoustic and / or optical signals can be transmitted to the user, signaling delivery at a reduced speed.
[0080] Another example of cold injection is Figure 7 . When the injection is started by pressing the push button, the motor may rotate a certain number of turns to compensate for tolerances and elasticity in the delivery mechanism. The number of turns is metered and kept below a stored initiation value of an initiation zone 37 defining a thrust range 40. Once non-rotation is detected by the detector, the target speed is first reduced to zero before automatically setting to a reduced target speed. In the absence of rotation of the motor, a transition time is required, which may be less than one minute, preferably less than 30 seconds, to relax the stress initially accumulated in the drive train. After the transition time, the target rotational speed for the motor and then the target linear speed for the piston rod are set to the reduced speed. Once the final position for the piston rod is reached, the non-rotation of the motor will be detected in the final zone 38 and the rotational speed will be permanently reduced to zero. Optionally, after the cold injection is completed, a signal is transmitted to the user.
[0081] Another example of a cold injection for including occlusion detection is in Figure 8 . The detector is actuated in the initiation zone 37 and the target speed is reduced to a reduced speed after a transition time. The drug is delivered at a reduced speed and in a blocking zone 39 in the region of the thrust range 40 between the initiation zone 37 and the final zone 38, the detector is actuated again when the piston rod or plunger cannot advance due to a blockage in the fluid path. The control unit permanently sets the speed (in this case, the reduced target speed) to zero and optionally actuates an alarm signal. During the transition time for stress relief, the speed is temporarily reduced to zero. When the drug is delivered at the target speed, the blockage detection also operates (not shown in the schematic diagram). Optionally, an acoustic and / or optical alarm signal is transmitted to the user.
[0082] The delivery device for a drug delivery device may also include a pause button 8 which may be pressed during delivery at the target rate or at a reduced rate ( Fig. 9 and Fig.10 , indicated by "P"). In the event that the patient feels discomfort during delivery, the pause button 8 can be pressed. Discomfort can be due to a cold injection, as the injected liquid has a lower temperature and a higher viscosity, such as Fig.10 Alternatively, the active ingredient is delivered at a target rate, but the active ingredient itself may cause discomfort such as headache ( Fig. 9 ). The pause button can be pressed repeatedly. The pause button is a separate button in this example, alternatively, if pressed for a long time (e.g. 4 seconds), the start button 3 switches to a pause button.
[0083] Parts Annotation
[0084] 1 Wearable Push Injector
[0085] 2 Shell
[0086] 3Start button
[0087] 4 Release lining
[0088] 5 Adhesive Patches
[0089] 6Observation window
[0090] 7 Status Indicator
[0091] 8 Pause button (optional)
[0092] 9 pull tabs
[0093] 10LED indicator
[0094] 11Control unit, printed circuit board
[0095] 12LED lights
[0096] 13 Transparent section shell
[0097] 14 Piston rod
[0098] 15 Batteries
[0099] 16 Battery Holder
[0100] 17 Electric Motor
[0101] 18-pin unit
[0102] 19Conveying device
[0103] 20 segments
[0104] 21 threaded rod
[0105] 22 first section
[0106] 23 Final Segment
[0107] 24 Gear unit
[0108] 25 Camshaft
[0109] 26 Skin insertion mechanism
[0110] 27-cylinder needle insertion mechanism
[0111] 28 tubes
[0112] 29 Skin Needle
[0113] 30-tube needle
[0114] 31 contacts
[0115] 32 barrels
[0116] 33 Plunger
[0117] 34 Neck
[0118] 35 diaphragm / crimp
[0119] 36 "P" Pause Button
[0120] 37 Triggering Zone
[0121] 38 Final Zone
[0122] 39 Blockage Zone
[0123] 40 thrust range.
Claims
1. A delivery device (19) for a drug delivery device, comprising: The piston rod (14) can be advanced along the thrust axis from an initial position to a final position, defining a thrust range (40), a detector configured to detect when the piston rod (14) reaches the final position, a conveying mechanism configured to advance the piston rod (14) along the thrust axis, a control unit (11) configured to control the forward speed of the piston rod (14) at a target speed, The thrust range can be divided into at least two regions: a final zone (38), whereby when the piston rod (14) reaches the final position, once the detector detects a stop of the piston rod (14), the control unit reduces the target speed to zero, and Wherein if the detector detects a standstill of the piston rod (14) in the initiation zone (37) of the thrust range, the target speed is reduced to a reduced speed.
2. The conveying device according to claim 1, wherein: The initiation zone (37) is defined by less than 30% of the thrust range (40) reached by the piston rod (14), and the final zone (38) begins above 80% of the thrust range (40).
3. The conveying device according to claim 2, wherein: The target speed is reduced stepwise or continuously to zero or to the reduced speed.
4. The conveying device according to claim 3, wherein: The reduced speed is less than 60% of the target speed.
5. The conveying device according to claim 4, wherein: In the initiation zone (37), the target speed is first reduced to zero before being set to the reduced speed.
6. A delivery device according to any one of the preceding claims, wherein: The piston rod (14) is advanced using an electric drive including an electric motor (17), and wherein the detector is actuated by detecting no rotation or limited rotation of the electric motor (17).
7. The conveying device according to claim 6, wherein: The detector detects the rotation or non-rotation of the motor (17) by measuring the number of steps of the motor (17), or by measuring a back electromotive force signal, or by using an encoder, or by measuring a motor current.
8. The conveying device according to claim 7, wherein: The control unit (11) actuates the motor (17) for advancing the piston rod (14) at the target speed by rotating the motor at the target rotational speed, and wherein, when the final position is detected by the detector in the final zone (38), the control unit (11) reduces the target rotational speed to zero, or when the detector is actuated in the initiation zone (37), the control unit (11) reduces the target rotational speed to a reduced rotational speed for advancing the piston rod (14) at the reduced speed.
9. The conveying device according to claim 8, wherein: The control unit (11) receives information from the detector and measures and meters the number of revolutions or steps of the motor (17), and compares the accumulated number of revolutions or steps with a stored value, and if the accumulated value is lower than a stored trigger value when no rotation is detected, the target rotation speed is reduced to the reduced rotation speed or to zero before applying the reduced rotation speed, and if the accumulated value is higher than a stored upper limit value, the target rotation speed is reduced to zero.
10. The conveying device according to claim 9, wherein: The control unit (11) actuates a first optical and / or acoustic signal when the piston rod (14) moves at the target speed, actuates a second optical and / or acoustic signal different from the first signal when the piston rod (14) moves at the reduced target speed, and actuates a third optical and / or acoustic signal different from the first signal and the second signal when the piston rod (14) reaches the final position.
11. The delivery device according to claim 10, wherein: When the accumulated number of revolutions is between the trigger value and the upper limit value, the target rotation speed is reduced to zero, and the control unit (11) actuates a fourth acoustic and / or optical alarm signal, indicating that a blockage has occurred in a blockage zone (39) between the trigger zone (37) and the final zone (38), preventing the drug from being discharged from the device.
12. The delivery device according to claim 8 to claim 11, further comprising a pause button (8) which, when pressed, pauses drug delivery by temporarily setting the target rotational speed of the motor (17) to zero.
13. A drug delivery device comprising a delivery device (19) according to claim 1 to claim 12, further comprising a reservoir (32) containing a drug and a plunger (33) movable within the reservoir (32) by the piston rod.
14. The drug delivery device of claim 13, wherein: The initial position of the piston rod (14) is defined by the plunger position for a full reservoir (32), and wherein the final position is defined by the plunger engaging a neck region (34) of the reservoir (32) preventing further advancement of the plunger.
15. The drug delivery device of claim 14, wherein: The delivery device is a wearable bolus injector (1).
